Literature DB >> 18662286

A limited sampling strategy for tacrolimus in renal transplant patients.

Binu S Mathew1, Denise H Fleming, Visalakshi Jeyaseelan, Sujith J Chandy, V M Annapandian, P K Subbanna, George T John.   

Abstract

AIMS: To develop and validate limited sampling strategy (LSS) equations to estimate area under the curve (AUC(0-12)) in renal transplant patients.
METHODS: Twenty-nine renal transplant patients (3-6 months post transplant) who were at steady state with respect to tacrolimus kinetics were included in this study. The blood samples starting with the predose (trough) and collected at fixed time points for 12 h were analysed by microparticle enzyme immunoassay. Linear regression analysis estimated the correlations of tacrolimus concentrations at different sampling time points with the total measured AUC(0-12). By applying multiple stepwise linear regression analysis, LSS equations with acceptable correlation coefficients (R(2)), bias and precision were identified. The predictive performance of these models was validated by the jackknife technique.
RESULTS: Three models were identified, all with R(2) > or = 0.907. Two point models included one with trough (C(0)) and 1.5 h postdose (C(1.5)), another with trough and 4 h postdose. Increasing the number of sampling time points to more than two increased R(2) marginally (0.951 to 0.990). After jackknife validation, the two sampling time point (trough and 1.5 h postdose) model accurately predicted AUC(0-12). Regression coefficient R(2) = 0.951, intraclass correlation = 0.976, bias [95% confidence interval (CI)] 0.53% (-2.63, 3.69) and precision (95% CI) 6.35% (4.36, 8.35).
CONCLUSION: The two-point LSS equation [AUC(0-12) = 19.16 + (6.75.C(0)) + (3.33.C1.5)] can be used as a predictable and accurate measure of AUC(0-12) in stable renal transplant patients prescribed prednisolone and mycophenolate.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18662286      PMCID: PMC2561121          DOI: 10.1111/j.1365-2125.2008.03251.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  22 in total

1.  Low systemic exposure to tacrolimus correlates with acute rejection.

Authors:  N A Undre; J van Hooff; M Christiaans; Y Vanrenterghem; J Donck; U Heeman; M Kohnle; B Zanker; W Land; J M Morales; A Andrés; A Schäfer; P Stevenson
Journal:  Transplant Proc       Date:  1999 Feb-Mar       Impact factor: 1.066

2.  Statistical measures of clinical agreement.

Authors:  L Jeyaseelan; P S Rao
Journal:  Natl Med J India       Date:  1992 Nov-Dec       Impact factor: 0.537

3.  Limited-sampling strategy models for estimating the pharmacokinetic parameters of 4-methylaminoantipyrine, an active metabolite of dipyrone.

Authors:  G Suarez-Kurtz; F M Ribeiro; R C Estrela; F L Vicente; C J Struchiner
Journal:  Braz J Med Biol Res       Date:  2001-11       Impact factor: 2.590

4.  Limited-sampling strategy models for itraconazole and hydroxy-itraconazole based on data from a bioequivalence study.

Authors:  G Suarez-Kurtz; F A Bozza; F L Vicente; C G Ponte; C J Struchiner
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

5.  An open-label, concentration-ranging trial of FK506 in primary kidney transplantation: a report of the United States Multicenter FK506 Kidney Transplant Group.

Authors:  D A Laskow; F Vincenti; J F Neylan; R Mendez; A J Matas
Journal:  Transplantation       Date:  1996-10-15       Impact factor: 4.939

6.  Tacrolimus versus cyclosporin for immunosuppression in renal transplantation: meta-analysis of randomised trials.

Authors:  G A Knoll; R C Bell
Journal:  BMJ       Date:  1999-04-24

7.  Effective oral administration of tacrolimus in renal transplant recipients.

Authors:  M Kimikawa; K Kamoya; H Toma; S Teraoka
Journal:  Clin Transplant       Date:  2001-10       Impact factor: 2.863

8.  Tacrolimus whole blood concentrations correlate closely to side-effects in renal transplant recipients.

Authors:  Y Böttiger; C Brattström; G Tydén; J Säwe; C G Groth
Journal:  Br J Clin Pharmacol       Date:  1999-09       Impact factor: 4.335

9.  Clinical efficacy and toxicity profile of tacrolimus and mycophenolic acid in relation to combined long-term pharmacokinetics in de novo renal allograft recipients.

Authors:  Dirk R J Kuypers; Kathleen Claes; Pieter Evenepoel; Bart Maes; Yves Vanrenterghem
Journal:  Clin Pharmacol Ther       Date:  2004-05       Impact factor: 6.875

10.  C2 (2-h) levels are not superior to trough levels as estimates of the area under the curve in tacrolimus-treated renal-transplant patients.

Authors:  Kaj Jørgensen; Johan Povlsen; Søren Madsen; Melvin Madsen; Hans Hansen; Asger Pedersen; Else-Marie Heinsvig; Jørgen Poulsen
Journal:  Nephrol Dial Transplant       Date:  2002-08       Impact factor: 5.992

View more
  13 in total

1.  Evaluation of limited sampling methods for estimation of tacrolimus exposure in adult kidney transplant recipients.

Authors:  Katherine A Barraclough; Nicole M Isbel; Carl M Kirkpatrick; Katie J Lee; Paul J Taylor; David W Johnson; Scott B Campbell; Diana R Leary; Christine E Staatz
Journal:  Br J Clin Pharmacol       Date:  2011-02       Impact factor: 4.335

Review 2.  Once- versus twice-daily tacrolimus: are the formulations truly equivalent?

Authors:  Katherine A Barraclough; Nicole M Isbel; David W Johnson; Scott B Campbell; Christine E Staatz
Journal:  Drugs       Date:  2011-08-20       Impact factor: 9.546

3.  Tacrolimus dosing in Chinese renal transplant recipients: a population-based pharmacogenetics study.

Authors:  Liang Li; Chuan-Jiang Li; Lei Zheng; Yan-Jun Zhang; Hai-Xia Jiang; Bo Si-Tu; Zhong-Hai Li
Journal:  Eur J Clin Pharmacol       Date:  2011-02-18       Impact factor: 2.953

4.  Statistical tools for dose individualization of mycophenolic acid and tacrolimus co-administered during the first month after renal transplantation.

Authors:  Flora T Musuamba; Michel Mourad; Vincent Haufroid; Martine De Meyer; Arnaud Capron; Isabelle K Delattre; Roger K Verbeeck; Pierre Wallemacq
Journal:  Br J Clin Pharmacol       Date:  2013-05       Impact factor: 4.335

5.  Gender-dependent predictable pharmacokinetic method for tacrolimus exposure monitoring in kidney transplant patients.

Authors:  Radmila Velickovic-Radovanovic; Momir Mikov; Aleksandra Catic-Djordjevic; Nikola Stefanovic; Branka Mitic; Goran Paunovic; Tatjana Cvetkovic
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2014-03-05       Impact factor: 2.441

6.  A randomized pharmacokinetic study of generic tacrolimus versus reference tacrolimus in kidney transplant recipients.

Authors:  R R Alloway; B Sadaka; J Trofe-Clark; A Wiland; R D Bloom
Journal:  Am J Transplant       Date:  2012-07-03       Impact factor: 8.086

7.  Population pharmacokinetics of immediate- and prolonged-release tacrolimus formulations in liver, kidney and heart transplant recipients.

Authors:  Zheng Lu; Peter Bonate; James Keirns
Journal:  Br J Clin Pharmacol       Date:  2019-06-07       Impact factor: 4.335

8.  A review on therapeutic drug monitoring of immunosuppressant drugs.

Authors:  Niloufar Mohammadpour; Sepideh Elyasi; Naser Vahdati; Amir Hooshang Mohammadpour; Jamal Shamsara
Journal:  Iran J Basic Med Sci       Date:  2011-11       Impact factor: 2.699

9.  Combined approach with therapeutic drug monitoring and pharmacogenomics in renal transplant recipients.

Authors:  S Manvizhi; B S Mathew; D H Fleming; G Basu; G T John
Journal:  Indian J Nephrol       Date:  2013-01

10.  The Population Pharmacokinetic Models of Tacrolimus in Chinese Adult Liver Transplantation Patients.

Authors:  Liqin Zhu; Hao Wang; Xiaoye Sun; Wei Rao; Wei Qu; Yuan Zhang; Liying Sun
Journal:  J Pharm (Cairo)       Date:  2014-02-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.